MBLAC1

Summary

MBLAC1 (metallo-beta-lactamase domain containing 1, HGNC:22180) is a protein-coding gene on chromosome 7q22.1, encoding Metallo-beta-lactamase domain-containing protein 1 (A4D2B0). Endoribonuclease that catalyzes the hydrolysis of histone-coding pre-mRNA 3’-end.

Enables RNA endonuclease activity and metal ion binding activity. Involved in histone mRNA metabolic process; mRNA 3’-end processing; and positive regulation of G1/S transition of mitotic cell cycle. Located in cytoplasm and nucleus.

Source: NCBI Gene 255374 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 13 total — 1 likely-pathogenic
• MANE Select transcript: NM_203397

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22180
Approved symbol	MBLAC1
Name	metallo-beta-lactamase domain containing 1
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC49416
Ensembl gene	ENSG00000214309
Ensembl biotype	protein_coding
OMIM	620906
Entrez	255374

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000398075, ENST00000421390, ENST00000905248

RefSeq mRNA: 1 — MANE Select: NM_203397 NM_203397

CCDS: CCDS43620

Canonical transcript exons

ENST00000398075 — 2 exons

Exon	Start	End
ENSE00001531468	100127368	100128495
ENSE00001531469	100126967	100127064

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 86.80.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7196 / max 27.0525, expressed in 435 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79930	0.7196	435

Top tissues by expression

226 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.80	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.41	silver quality
prefrontal cortex	UBERON:0000451	76.96	gold quality
tendon of biceps brachii	UBERON:0008188	76.65	silver quality
Brodmann (1909) area 9	UBERON:0013540	75.98	gold quality
right hemisphere of cerebellum	UBERON:0014890	75.93	gold quality
right frontal lobe	UBERON:0002810	75.63	gold quality
cerebellar hemisphere	UBERON:0002245	75.28	gold quality
anterior cingulate cortex	UBERON:0009835	75.21	gold quality
cerebellar cortex	UBERON:0002129	75.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	74.88	gold quality
cerebellum	UBERON:0002037	74.61	gold quality
frontal cortex	UBERON:0001870	74.32	gold quality
endothelial cell	CL:0000115	74.26	silver quality
neocortex	UBERON:0001950	74.10	gold quality
apex of heart	UBERON:0002098	73.85	gold quality
cerebral cortex	UBERON:0000956	72.73	gold quality
mucosa of transverse colon	UBERON:0004991	72.26	gold quality
lower esophagus muscularis layer	UBERON:0035833	71.85	gold quality
lower esophagus	UBERON:0013473	71.80	gold quality
nucleus accumbens	UBERON:0001882	71.42	gold quality
cortical plate	UBERON:0005343	71.41	gold quality
brain	UBERON:0000955	71.27	gold quality
forebrain	UBERON:0001890	71.26	gold quality
right ovary	UBERON:0002118	71.08	gold quality
right atrium auricular region	UBERON:0006631	71.08	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	71.05	gold quality
amygdala	UBERON:0001876	71.01	gold quality
cardiac atrium	UBERON:0002081	70.96	gold quality
putamen	UBERON:0001874	70.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.88

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting MBLAC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-4732-3P	97.15	65.45	881
HSA-MIR-345-5P	96.40	66.43	663

Literature-anchored findings (GeneRIF, showing 1)

• The cellular, genetic, biochemical, substrate selectivity, and crystallographic studies have been reported providing evidence that endoribonuclease, MBLAC1, is selective for 3’ processing of replication-dependent histone pre-mRNA during the S-phase of the cell cycle. (PMID:30507380)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mblac1	ENSDARG00000077314
mus_musculus	Mblac1	ENSMUSG00000049285
rattus_norvegicus	Mblac1	ENSRNOG00000082402
drosophila_melanogaster	CG9117	FBGN0031766
caenorhabditis_elegans		WBGENE00018738

Protein

Protein identifiers

Metallo-beta-lactamase domain-containing protein 1 — A4D2B0 (reviewed: A4D2B0)

Alternative names: Endoribonuclease MBLAC1

All UniProt accessions (2): A4D2B0, C9JAV3

UniProt curated annotations — full annotation on UniProt →

Function. Endoribonuclease that catalyzes the hydrolysis of histone-coding pre-mRNA 3’-end. Involved in histone pre-mRNA processing during the S-phase of the cell cycle, which is required for entering/progressing through S-phase. Cleaves histone pre-mRNA at a major and a minor cleavage site after the 5’-ACCCA-3’ and the 5’-ACCCACA-3’ sequence, respectively, and located downstream of the stem-loop. May require the presence of the HDE element located at the histone pre-RNA 3’-end to avoid non-specific cleavage.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm. Cytosol. Nucleus.

Cofactor. Binds 2 Zn(2+) ions per subunit.

Domain organisation. Contains four of the five characteristic MBL-fold metal-binding motifs, with two waters completing metal coordination.

Similarity. Belongs to the metallo-beta-lactamase superfamily. Glyoxalase II family.

RefSeq proteins (1): NP_981942* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001279	Metallo-B-lactamas	Domain
IPR036866	RibonucZ/Hydroxyglut_hydro	Homologous_superfamily
IPR039344	MBLAC1	Family

Pfam: PF00753

Catalyzed reactions (Rhea), 1 shown:

• a ribonucleotidyl-ribonucleotide-RNA + H2O = a 3’-end ribonucleotide-RNA + a 5’-end 5’-phospho-ribonucleoside-RNA + H(+) (RHEA:68096)

UniProt features (44 total): strand 16, binding site 8, helix 7, mutagenesis site 3, turn 3, region of interest 2, sequence variant 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4V0H	X-RAY DIFFRACTION	1.79

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A4D2B0-F1	89.22	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 231; 114; 116; 118; 119; 169; 192; 192

Mutagenesis-validated functional residues (3):

Position	Phenotype
169	loss of endoribonuclease activity; when associated with a-192 and a-231.
192	loss of endoribonuclease activity; when associated with a-169 and a-231.
231	loss of endoribonuclease activity; when associated with a-169 and a-192.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 62 (showing top): GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GOBP_POSITIVE_REGULATION_OF_G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE, GOMF_RNA_ENDONUCLEASE_ACTIVITY, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_MRNA_3_END_PROCESSING, GOBP_REGULATION_OF_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_MITOTIC_CELL_CYCLE, GOBP_HISTONE_MRNA_METABOLIC_PROCESS

GO Biological Process (3): histone mRNA metabolic process (GO:0008334), mRNA 3’-end processing (GO:0031124), positive regulation of G1/S transition of mitotic cell cycle (GO:1900087)

GO Molecular Function (4): RNA endonuclease activity (GO:0004521), hydrolase activity (GO:0016787), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
mRNA metabolic process	1
mRNA processing	1
RNA 3’-end processing	1
G1/S transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of cell cycle G1/S phase transition	1
regulation of G1/S transition of mitotic cell cycle	1
endonuclease activity	1
RNA nuclease activity	1
catalytic activity	1
cation binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

240 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MBLAC1	MBLAC2	Q68D91	664
MBLAC1	LACTB2	Q53H82	642
MBLAC1	ELAC1	Q9H777	531
MBLAC1	HAGHL	Q6PII5	497
MBLAC1	DCLRE1A	Q6PJP8	493
MBLAC1	ATOSA	Q32MH5	489
MBLAC1	HAGH	Q16775	479
MBLAC1	ZC3H6	P61129	479
MBLAC1	ELAC2	Q9BQ52	478
MBLAC1	INTS9	Q9NV88	465
MBLAC1	KBTBD4	Q9NVX7	456
MBLAC1	WASHC4	Q2M389	447
MBLAC1	ISG20L2	Q9H9L3	425
MBLAC1	DCLRE1B	Q9H816	415
MBLAC1	PNKD	Q8N490	399

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MBLAC1	H1-7	psi-mi:“MI:0914”(association)	0.560
MBLAC1	H1-7	psi-mi:“MI:0915”(physical association)	0.560
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350

BioGRID (16): H1FNT (Affinity Capture-MS), CLP1 (Affinity Capture-MS), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), MBLAC1 (Two-hybrid), C10orf55 (Two-hybrid), MBLAC1 (Affinity Capture-MS), MBLAC1 (Affinity Capture-RNA)

ESM2 similar proteins: A2XFU4, A2XFU5, A2XVN3, A2YQ58, A3AVP1, A4D2B0, A4IFA8, A7HDG9, A8ID74, A8IF44, A8J1V4, A8MPS7, B1WBV0, B4UH39, B8JE35, G8XHD8, O86507, P29784, P52824, Q08325, Q0D3F2, Q0D9V6, Q0DSH9, Q10MI9, Q1CW46, Q2HJB0, Q2IQ95, Q2RSY6, Q498J9, Q50863, Q50864, Q53JI9, Q53U11, Q566Q8, Q5GA22, Q5NAI7, Q6AYD1, Q72DW3, Q758T2, Q82JN8

Diamond homologs: A4D2B0, Q11123, Q2HJB0, Q498J9, Q6AYD1, Q8BWY4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

13 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	12
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3358894	NM_203397.3(MBLAC1):c.-28-1G>A	Likely pathogenic

SpliceAI

256 predictions. Top by Δscore:

Variant	Effect	Δscore
7:100127367:GCCC:G	acceptor_gain	0.9900
7:100127130:GGAC:G	donor_gain	0.9800
7:100127131:G:GT	donor_gain	0.9800
7:100127366:A:AG	acceptor_gain	0.9800
7:100127367:G:GG	acceptor_gain	0.9800
7:100127037:G:GG	donor_gain	0.9700
7:100127104:G:GT	donor_gain	0.9700
7:100127367:GC:G	acceptor_gain	0.9700
7:100127134:G:GG	donor_gain	0.9600
7:100127367:GCC:G	acceptor_gain	0.9600
7:100127366:AGCCC:A	acceptor_gain	0.9500
7:100127367:GCCCG:G	acceptor_gain	0.9500
7:100127105:A:T	donor_gain	0.9400
7:100127202:G:GT	donor_gain	0.9400
7:100127043:C:T	donor_gain	0.9300
7:100127093:G:T	donor_gain	0.9200
7:100126994:G:GT	donor_gain	0.9100
7:100127364:CCA:C	acceptor_loss	0.9100
7:100127131:GAC:G	donor_gain	0.9000
7:100127178:G:GT	donor_gain	0.9000
7:100127363:CCCAG:C	acceptor_gain	0.8900
7:100127364:CCAGC:C	acceptor_gain	0.8900
7:100127365:CAGCC:C	acceptor_gain	0.8900
7:100127129:AGGAC:A	donor_gain	0.8800
7:100127130:GGACG:G	donor_gain	0.8800
7:100127046:G:GT	donor_gain	0.8700
7:100127036:A:AG	donor_gain	0.8600
7:100127179:G:T	donor_gain	0.8600
7:100127366:AG:A	acceptor_gain	0.8600
7:100127367:G:T	acceptor_gain	0.8600

AlphaMissense

1657 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:100127921:A:C	S176R	0.989
7:100127923:C:A	S176R	0.989
7:100127923:C:G	S176R	0.989
7:100127975:T:C	F194L	0.983
7:100127977:T:A	F194L	0.983
7:100127977:T:G	F194L	0.983
7:100127749:T:A	D118E	0.977
7:100127749:T:G	D118E	0.977
7:100127748:A:T	D118V	0.975
7:100127970:A:T	D192V	0.975
7:100128045:G:C	R217P	0.975
7:100127971:T:A	D192E	0.974
7:100127971:T:G	D192E	0.974
7:100128098:T:C	F235L	0.972
7:100128100:T:A	F235L	0.972
7:100128100:T:G	F235L	0.972
7:100127976:T:C	F194S	0.969
7:100128014:A:C	S207R	0.969
7:100128016:T:A	S207R	0.969
7:100128016:T:G	S207R	0.969
7:100128075:T:A	V227D	0.969
7:100128004:G:C	W203C	0.967
7:100128004:G:T	W203C	0.967
7:100127771:T:C	F126L	0.963
7:100127772:T:C	F126S	0.963
7:100127773:C:A	F126L	0.963
7:100127773:C:G	F126L	0.963
7:100127748:A:C	D118A	0.960
7:100127761:C:A	N122K	0.960
7:100127761:C:G	N122K	0.960

dbSNP variants (sampled 300 via entrez): RS1000392813 (7:100128116 G>T), RS1000694652 (7:100126631 A>G), RS1001735567 (7:100125562 G>A), RS1002288845 (7:100125423 T>C), RS1002674646 (7:100126929 G>A), RS1003158022 (7:100126779 T>A,C), RS1004086645 (7:100127995 G>A,T), RS1004314645 (7:100125759 G>C), RS1004751809 (7:100126015 T>C), RS1005215226 (7:100125422 C>T), RS1006252036 (7:100126458 G>C), RS1006597026 (7:100127496 T>G), RS1007039184 (7:100127699 G>A,C,T), RS1007270102 (7:100127389 C>A,T), RS1008189590 (7:100128980 T>C)

Disease associations

OMIM: gene MIM:620906 | disease phenotypes: MIM:192500

GenCC curated gene-disease

Mondo (1): familial long QT syndrome (MONDO:0019171)

Orphanet (2): Romano-Ward syndrome (Orphanet:101016), Congenital long QT syndrome (Orphanet:768)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST005196_147	Coronary artery disease	2.000000e-06
GCST009281_6	Microalbuminuria in type 1 diabetes	1.000000e-08
GCST010002_259	Refractive error	3.000000e-16
GCST010083_207	Hemoglobin levels	6.000000e-26
GCST010702_48	Subcortical volume (MOSTest)	6.000000e-10
GCST010703_289	Brain morphology (MOSTest)	6.000000e-15
GCST90002383_428	Hematocrit	2.000000e-27

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement
EFO:0004346	neuroimaging measurement
EFO:0004348	hematocrit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
abrine	increases expression	1
jinfukang	increases expression	1
Glyphosate	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Potassium Dichromate	increases expression	1
Sodium Dodecyl Sulfate	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Valproic Acid	affects expression	1
2,4-Dichlorophenoxyacetic Acid	decreases expression	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea